Tetracycline (Tet)-controlled transcriptional activators allow for the inducible expression of protein-coding genes or shRNAs, and are frequently used to decipher gene function in cultured cells and in vivo [1] . The system is based on the bacterial Tet operon that mediates resistance to Tet derivatives, such as doxycycline (Dox). In the Tet-off system, fusion of a Tet repressor protein with the transcriptional activation domain of the herpes simplex virus protein VP16 results in a Tet-controlled transcriptional activator (tTA), which constitutively binds to Tet-responsive elements (TRE), but is inhibited in its transcriptional activity by Dox [1] . In contrast, in the more frequently used Tet-on system, a mutant tTA-version generates a reverse tTA (rtTA) that is only recruited to the TRE upon Dox binding and then mediates transgene expression [1] . Since the Tet-system allows transgene expression in a tissue-specific and temporal manner, it has been extensively used for regulating expression of oncogenes or silencing of tumor suppressor genes [1] [2] [3] . Despite its enormous success, however, we report here that, irrespective of the transgene, the Tet-system might compromise activated T-cells, thereby providing a cautionary note for its use in immunological studies.
To investigate T-cell responses, we used transgenic mice carrying an advanced Tet-on transactivator, driving expression of a miR30-based shRNA in frame with a turboGFP reporter. To reduce effects associated with random integration, the Dox-inducible shRNA-reporter transgene was delivered by a recombinase-mediated cassette exchange approach into the type-I collagen (Col1a1) locus. During an in-depth analysis of the transgenic mice, we discovered that specific splenic T-cell populations were absent not only in those mice expressing shRNAs targeting particular mRNAs, but surprisingly also in mice carrying a control shRNA for Renilla luciferase. These effects were independent of the promoter for rtTA expression, and observed in independent mouse lineages of both ROSA26 and CAG promoter-driven systems. Although total CD4
+ T-cells in the spleen were only marginally reduced, antigen-experienced CD4 + Tcells, which we characterized as CD44 + and CD62L low , were nearly absent in the GFP-positive fractions (Fig. 1) . We confirmed the reduction of activated T-cells in the GFPpositive population by CD25 and CD69 staining (Fig. 1) . Importantly, disappearance of antigen-experienced T-cells was not mediated by Dox itself, since Dox-treated mice lacking rtTA expression exhibited normal numbers of activated T-cells (Fig. 1) . Already 6-10 days of Dox treatment were sufficient to trigger a profound reduction in CD25 + /CD44 + /CD4 + T-cells, which characterize effector memory or regulatory T-cells. Thus, their rapid disappearance suggests that Dox-activated rtTA/turboGFP expression induces toxicity in these cells (Fig. 1) . Interestingly, the frequency of double-negative thymocytes expressing CD25 and CD44 was not altered (Suppl. Fig. S1 ). However, antigen-experienced GFP-positive CD8 + T-cells, characterized by CD44 expression, were reduced similarly to the CD4 + lineage (Suppl. Fig. S2 ).
Our findings demonstrate that, in contrast to thymocytes and naïve T-cells, antigen-experienced T-cells are depleted using the rtTA-system. Hundreds of mouse models have been generated with the rtTA-system for the expression of oncogenes or the silencing of tumor suppressor genes. In the latter condition, the blunting effects on T-cell activation might be even advantageous to identifying novel tumor suppressors. More recently, Tet-transactivators proved very useful for modulating gene activities by CRISPR/Cas9 and Cre/LoxP technologies [4, 5] . Adverse effects of the rtTAprotein might not be restricted to activated T-cells, but could also affect other cell populations [6, 7] . Importantly, a recent study provided compelling evidence that not only activated T-cells, but also B-cells are diminished in tTAtransgenic mice [8] . This study further showed an inhibition of lymphocyte depletion by Bcl-2, suggesting that tTA expression triggers an apoptotic response. Thus, in addition to the ability of Dox to interfere with mitochondrial functions [9] , these results provide a cautionary note for using proper controls to reveal potential side effects of Tet transactivator expression alone. Fig. 1 Quantification of antigen-experienced splenic T-cells in ROSA26-rtTA TRE-turboGFP-shRenilla mice. a Flow cytometric analysis of total splenocytes isolated from mice receiving 2 mg/ml doxycycline (Dox) for 4 weeks. Splenocytes were gated for CD4 
